ACE inhibitors in heart failure: Prospects and limitations

Cardiovascular Drugs and Therapy

Volumn 11, Issue SUPPL. 1, 1997, Pages 285-290

  Pitt, Bertram ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

ACE inhibitors; Angiotensin II type 1 receptor blocking drugs; Bradykinin; Heart failure

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LOSARTAN; QUINAPRIL; SPIRONOLACTONE;

ARTICLE; ATHEROSCLEROSIS; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; KIDNEY DISEASE; LIVER METABOLISM; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SYSTOLE; URINARY EXCRETION;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; CARDIAC OUTPUT, LOW; COUGH; CREATININE; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; VENTRICULAR FUNCTION, LEFT;

EID: 0030917664     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007795915009     Document Type: Article

References (42)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
3. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991;324: 303-310.
4. Pfeffer MA, Braunwald E, Moye LA, et al. on behalf of the SAVE Investigators. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-677.
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:812-828.
6. Gruppo Italiano per lo Studio delia Sopravvivenza nell'infarto Miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
7. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
8. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-687.
9. Ambrosioni E, Borhi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-85.
10. Vaughan DE, Pfeffer MA Angiotensin converting enzyme inhibitors and cardiovascular remodeling. Cardiovasc Res 1994;28:159-165.
11. St. John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 1994;89:68-75.
12. Flather MD, Lonn EM, Yusuf S. Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: Evidence from the larger randomized controlled trials. J Cardiovasc Risk 1995;2:423-428.
13. Flaherty J. Personal communication.
14. Ayanian J, Hauptman P, Guadagnoli E, Antman E, Pashos C, McNeil B. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 1994;331:1136-1142.
15. Gehr TWB, Sica DA, Grasela DM, Fakhry I, Davis J, Duchin KL. Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients. Eur J Clin Pharmacol 1991;41:165-169.
16. Fletcher A, Palmer A, Bulpitt C. Cough with angiotensin converting enzyme inhibitors: How much of a problem? J Hypertens 1994;12:S43-S47.
17. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-445.
18. Timmermans P BMWM, Smight RD. A new class of therapeutic agents: The angiotensin II receptor antagonists. Cardiologia 1994;39:397-400.
19. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: Reversal by the bradykinin antagonist HOE140. J Cardiovasc Pharmacol 1993;21:996-1003.
20. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerosis coronary arteries. N Engl J Med 1986;315:1046-1051.
21. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, Zelir R. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69:1596-1601.
22. Werns SW, Walton JA, Hsia HH, Nabel EG, Sanz ML, Pitt B. Evidence of endothelial dysfunction in angiographically normal coronary arteries of patients with coronary artery disease. Circulation 1989;79:287-291.
23. Rafflenbuhl W, Bassenge E, Lichtlen P. Konkurrenz zwischen endothelabhangiger und nitroglycerin-induzierter koronarer vasodilatation. Z Kardiologie 1989;78:45-47.
24. Pitt B, Chang P, Timmermans P BMWWM. Angiotensin II receptor antagonists in heart failure: Rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc Drugs Ther 1995;9:693-700.
25. Pouleur H, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction during enalapril therapy: Relationship with neuro-hormonal reactivation. Circulation 1993;88:I293.
26. Vagelos R, Yee G, Boyle M, et al. Failure of low but not high dose chronic enalapril therapy to suppress serum angiotensin converting enzyme (ACE) activity in heart failure (abstr). J Am Coll Cardiol 1992;19:145.
27. Urata H, Konshita A, Misono K, Bumpus F, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human chymase. J Biol Chem 1990;265:22348-22357.
28. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-465.
29. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovasc Drugs Ther 1995;9:145-149.
30. The Rales Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. (The Randomized ALdactibe Evaluation Study (RALES)). Am J Cardiol 1996;78:902-907.
31. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B for the Quinapril Heart Failure Trial Investigators. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: A double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol 1993;22: 1557-1563.
32. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-1178.
33. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. Circulation 1994;90:1731-1738.
34. Pitt B. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. Am Heart J 1994; 128:1328-1332.
35. Keidar S, Brook JG, Aviram M. Angitensin II enhanced lipid peroxidation of low-density lipoprotein. J Am Physiol Soc 1993;8:245-248.
36. Texter M, Lees RS, Pitt B Dinsmore RE, Uprichard ACG. The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Ther 1993;7:273-282.
37. Antonaccio MJ, Kerwin L. Pre and postjunctional inhibition of vascular sympathetic function by captopril in SHR: Implication of vascular angiotensin-II in hypertension and antihypertensive actions of captopril. Hypertension 1991;3:I54-62.
38. Sobotka PA, Brottman MD, Weitz Z, Birnbaum AJ, Skosey JL, Zarling EJ. Elevated breath pentane in heart failure reduced by free radical scavenger. Free Radic Biolo Med 1993;14:643-7.
39. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM. Effect of carvedilol on the survival of patients with chronic heart failure. Circulation 1995;92 (Suppl):I42.
40. Pitt B, Rouleau JL, Nicklas J, et al. for the PROFILE Investigators. Prognostic importance of the oxidation products of catecholamines (adrenochromes) in patients with heart failure. J Am Coll Cardiol 1995;25:177A.
41. Christopher TA, Lopez BL, Yue TL, Feuerstein GZ, Ruffolo RR, Jr. Ma XL. Carvedilol, a new beta-adrenoreceptor blocker, vasodilator and free-radical scavenger, exerts an anti-shock and endothelial protective effect in rat splanchnic ischemia and reperfusion. J Pharmacolo Exp Ther 1995; 273:64-71.
42. de Cavanagh EMV, Inserra F, Ferder L, Romano L, Ercole L, Fraga CG. Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Let 1995;361:22-24.